Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the available treatment options for first-line therapy of HBV
- Compare the advantages and disadvantages of current HBV treatment options
- Describe the clinical consequences of HBV resistance, focusing on prevention of resistance
- Recount the factors that determine whether to continue or change HBV therapy
Topics covered include:
- Introduction
- Antiviral Therapies for Chronic Hepatitis B
- Goals and Endpoints of HBV Treatment
- First-line Interferon-Based Therapy for Chronic Hepatitis B Infection
- First-line Nucleos(t)ide Analogue Treatment of Chronic Hepatitis B
- Entecavir for the Initial Treatment of Chronic Hepatitis B
- Tenofovir for the Initial Treatment of Chronic Hepatitis B
- Role of Combination Therapy With Recommended First-line Nucleos(t)ides
- Other Approved and Experimental Nucleos(t)ide Analogues for Treatment of HBV Infection
- Preventing Resistance to Nucleos(t)ide Analogues
- Management of Established Resistance
- HBV Treatment in Special Populations
- Unanswered Questions
- Implications for Clinical Practice
Abstract